Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553882 | 0.91 | IRAK4 (0.33) | IRAK4MAPK8MAPK9MAPK10PHGDH | |
| SCHEMBL4554738 | 0.91 | MAPK8 (0.33) | MAPK8MAPK9MAPK10PHGDH | |
| SCHEMBL4555121 | 0.88 | MAPK8 (0.35) | MAPK8MAPK9MAPK10PHGDH | |
| SCHEMBL4553442 | 0.85 | MEN1 (0.41) | PHGDH | |
| SCHEMBL4553761 | 0.85 | MAPK8 (0.31) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4554651 | 0.84 | NPY5R (0.34) | MAPK8MAPK9MAPK10PHGDH | |
| SCHEMBL4554437 | 0.83 | MAPK8 (0.32) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4554830 | 0.83 | OXER1 (0.31) | OXER1IRAK4PHGDH | |
| SCHEMBL4554504 | 0.79 | NPY5R (0.35) | — | |
| SCHEMBL4553884 | 0.77 | IRAK4 (0.33) | IRAK4PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |